Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
GLP-1 is also secreted by a small population of neurons in the hindbrain (Richard et al., 2015)
And beyond the scale, many people report better energy, clearer thinking, improved mood, and better control of blood sugar and blood pressure
The medication enters your bloodstream gradually through the surrounding capillaries
DOI: 10.1089/ars.2017.7051 93